ERBB2 and acute lymphoblastic leukemia: Thus, patients from the three cohorts were divided into eight groups according to the type and number of the altered gene they carried, including EGFR/KRAS_S (Patients with single EGFR/KRAS alteration), EGFR/KRAS_M (Patients with co‐occurring alterations of EGFR/KRAS and other seven driver genes), ALL/Others_S [Patients with single alteration in eight driver genes/others six driver genes (ROS1, MET, RET, ALK, ERBB2, BRAF)], and ALL/Others_M (Patients with multiple alterations in eight driver genes/other six driver genes) (Table 2).